Nausea

• 

  Subject Areas on Research

  • A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. 
  • A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. 
  • A comparison of three methods of pain control for posterior spinal fusions in adolescent idiopathic scoliosis. 
  • A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. 
  • A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. 
  • A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. 
  • A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. 
  • A twenty-six-year-old Trinidadian woman with dizziness, nausea, and vomiting. 
  • A1-A2 interposition grafting for surgical treatment of a giant "unclippable" A1 segment aneurysm. 
  • Abdominal migraine: prophylactic treatment and follow-up. 
  • Abdominal radiography in the emergency department: a prospective analysis. 
  • Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. 
  • Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. 
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study. 
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 
  • Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. 
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 
  • Appropriate Use of Antiemetics to Prevent Chemotherapy-Induced Nausea and Vomiting. 
  • Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. 
  • Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. 
  • Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. 
  • Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. 
  • Chemotherapy-induced nausea and vomiting. 
  • Children's coping strategies for chemotherapy-induced nausea and vomiting. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Clinical Reasoning: Two see or not two see-Is it really double vision? 
  • Clinical problem-solving. A key miscommunication--an 81-year-old woman presented to the emergency department with increasing abdominal distention, nausea, and vomiting. 
  • Clinico-pathologic conference: 12-year-old girl with fatigue, anemia, weight loss, abdominal distention, and occasional nausea and vomiting. 
  • Clostridium difficile infection in obstetric and gynecologic patients. 
  • Comprehensive care of the elderly patient with cancer. 
  • Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach. 
  • Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. 
  • Dietl's crisis: a syndrome of episodic abdominal pain of urologic origin that may present to a gastroenterologist. 
  • Differences between patients with cardiovascular disease and cancer referred for palliative care. 
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. 
  • Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. 
  • Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. 
  • Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. 
  • Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. 
  • Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. 
  • Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). 
  • Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. 
  • Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. 
  • Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. 
  • Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Eye pain after vitreoretinal surgery: a prospective study of 185 patients. 
  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. 
  • Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. 
  • Helical tomotherapy for bilateral breast cancer: Clinical experience. 
  • Hypnosis as adjuvant antiemetic therapy in childhood cancer. 
  • I look funny and I feel bad. Measurement of symptom distress. 
  • Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. 
  • Impact of data by Fujii and colleagues on the meta-analysis of metoclopramide for antiemetic prophylaxis in women undergoing Caesarean delivery under neuraxial anaesthesia. 
  • Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting. 
  • In reply: Spinal anesthesia for Cesarean delivery in obese parturients: is this the best option? 
  • Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia. 
  • Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. 
  • Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. 
  • Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. 
  • L-carnitine. 
  • Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials. 
  • Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. 
  • Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events. 
  • Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. 
  • Male and female rats exhibit comparable gaping behavior but activate brain regions differently during expression of conditioned nausea. 
  • Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. 
  • Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. 
  • Maternal influences on nausea and vomiting in early pregnancy. 
  • Metagenomics and chemotherapy-induced nausea: A roadmap for future research. 
  • Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. 
  • Midtrimester abortion induced by single intra-amniotic instillation of two dose schedules of 15(S)-15-methyl-prostaglandin F2alpha. 
  • Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. 
  • Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • Nausea and vomiting of pregnancy: role of human chorionic gonadotropin and 17-hydroxyprogesterone. 
  • Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment. 
  • Nausea, pain, fatigue, and multiple symptoms in hospitalized children with cancer. 
  • Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. 
  • Orthostatic intolerance and gastrointestinal motility in adolescents with nausea and abdominal pain. 
  • Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. 
  • P6 stimulation for the prevention of nausea and vomiting associated with cesarean delivery under neuraxial anesthesia: a systematic review of randomized controlled trials. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Patient preferences in advanced or recurrent ovarian cancer. 
  • Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. 
  • Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. 
  • Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. 
  • Pediatric orbital floor fractures: nausea/vomiting as signs of entrapment. 
  • Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. 
  • Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Physical Activity, the Childhood Cancer Symptom Cluster-Leukemia, and Cognitive Function: A Longitudinal Mediation Analysis. 
  • Postoperative nausea and vomiting. A retrospective analysis in patients undergoing elective craniotomy. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. 
  • Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. 
  • Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. 
  • Rebound intracranial hypertension: a complication of epidural blood patching for intracranial hypotension. 
  • Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. 
  • Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. 
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 
  • Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". 
  • Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. 
  • Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. 
  • SPINAL OR GENERAL ANESTHESIA FOR INGUINAL HERNIA REPAIR?A COMPARISON OF CERTAIN COMPLICATIONS IN A CONTROLLED SERIES. 
  • Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. 
  • Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. 
  • Scombroid fish poisoning. Outbreak traced to commercially canned tuna fish. 
  • Self-hypnosis as antiemetic therapy in children receiving chemotherapy. 
  • Sensory neuromodulators in functional nausea and vomiting: predictors of response. 
  • Severity and duration of nausea and vomiting symptoms in pregnancy and spontaneous abortion. 
  • Sickness behavior clustering in children with cancer. 
  • Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India. 
  • Single-dose oritavancin in the treatment of acute bacterial skin infections. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of the literature. 
  • Spinal-induced hypotension: Incidence, mechanisms, prophylaxis, and management: Summarizing 20 years of research. 
  • Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. 
  • Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. 
  • Symptom experiences of children and adolescents with cancer. 
  • Symptom management research in children with cancer. 
  • Temozolomide in pediatric low-grade glioma. 
  • The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The Longitudinal Parallel Process Analysis of Biomarkers of Oxidative Stress, Symptom Clusters, and Cognitive Function in Children With Leukemia. 
  • The evaluation of drug rechallenge: the casopitant Phase III program. 
  • The influence of oxidative stress on symptom occurrence, severity, and distress during childhood leukemia treatment. 
  • The meaning of adolescents' eating experiences during bone marrow transplant recovery. 
  • The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). 
  • The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. 
  • The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Three months in the symptom life of a teenage girl undergoing treatment for cancer. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Travelers' diarrhea. 
  • Treatment of migraine headache after ocular surgery with intravenous metoclopramide hydrochloride. 
  • Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 
  • Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 
  • Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey. 
  • Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure. 
  • Virtual reality as a distraction intervention for older children receiving chemotherapy. 
  • Virtual reality as a distraction intervention for women receiving chemotherapy. 
  • What We Do (and Don't) Know About the Health Effects of Cannabis and Whether Marijuana Is Medicine. 
  • What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. 
• 

  Keywords of People

  • Affronti, Mary Louise, Clinical Professor in the School of Nursing, School of Nursing